Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00546572 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
A Phase 3 study of Pneumococcal Infections, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 938
- Enrollment target
- 20
- Study locations
NCT00546572 is a Phase 3 study of Pneumococcal Infections that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 938 participants, above the 811-participant average among 10 other Pneumococcal Infections trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT00546572, a Phase 3 study of Pneumococcal Infections, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 938 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, tolerability and immunogenicity of study vaccines 13vPnC and 23vPS in older, healthy subjects who have previously received a dose of 23vPS at least 5 years ago. It will also evaluate the safety, tolerability and immunogenicity to a dose of 13vPnC 1 year after the initial dose of study vaccine.
Conditions Studied
Interventions
- BIOLOGICAL 13 valent Pneumococcal Conjugate Vaccine
- BIOLOGICAL 23vPS
Study Locations (20)
Florida
- Pfizer Investigational Site - Clearwater
- Pfizer Investigational Site - Coral Gables
- Pfizer Investigational Site - Jacksonville
- Pfizer Investigational Site - Pinellas Park
- Pfizer Investigational Site - Tampa
Georgia
- Pfizer Investigational Site - Atlanta
- Pfizer Investigational Site - Atlanta
- Pfizer Investigational Site - Stockbridge
Arizona
- Pfizer Investigational Site - Mesa
- Pfizer Investigational Site - Mesa
Minnesota
- Pfizer Investigational Site - Minneapolis
- Pfizer Investigational Site - Rochester
Alabama
- Pfizer Investigational Site - Mobile
California
- Pfizer Investigational Site - Fountain Valley
Colorado
- Pfizer Investigational Site - Denver
Connecticut
- Pfizer Investigational Site - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 938 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00546572
The ClinicalTrials.gov registry entry for NCT00546572 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 938 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 811-participant average among 10 other Pneumococcal Infections trials with a reported enrollment target (16% higher). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pneumococcal Infections appearing as the primary indexed condition, and to 2 interventions - of which 13 valent Pneumococcal Conjugate Vaccine is the first listed.
NCT00546572 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Georgia, Arizona.
Frequently Asked Questions
What is clinical trial NCT00546572 about?
NCT00546572 is a clinical study titled "Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)". This study will evaluate the safety, tolerability and immunogenicity of study vaccines 13vPnC and 23vPS in older, healthy subjects who have previously received a dose of 23vPS at least 5 years ago. It will also evaluate the safety, tolerability and immunogenicity to a dose of 13vPnC 1 year after the...
What is the current status of trial NCT00546572?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 938 participants. The study started on 2007-11. Estimated completion is 2010-07.
What conditions does trial NCT00546572 study?
This clinical trial studies the following conditions: Pneumococcal Infections.
What interventions are being tested in trial NCT00546572?
The interventions under investigation include: 13 valent Pneumococcal Conjugate Vaccine (BIOLOGICAL), 23vPS (BIOLOGICAL).
Who is sponsoring clinical trial NCT00546572?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00546572 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)
COMPLETED · Phase 3
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
COMPLETED · Phase 3
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
COMPLETED · Phase 3
-
A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
COMPLETED · Phase 3
-
Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.